US FDA reveals some PDUFA meeting details
This article was originally published in SRA
Executive Summary
Documents posted on the US Food and Drug Administration's website that contain summaries of meetings the agency has held with various stakeholders to discuss the reauthorisation of the Prescription Drug User Fee Act reveal that the drug industry has "agreed to include the $65 million in additional fee revenues for drug safety" in fiscal year 2012 in the base fee revenue amount for PDUFA V1.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.